Summit Therapeutics Inc’s recently made public that its Co-Chief Executive Officer Zanganeh Mahkam acquired Company’s shares for reported $5.89 million on Sep 10 ’25. In the deal valued at $17.68 per share,333,394 shares were bought. As a result of this transaction, Zanganeh Mahkam now holds 556,088,090 shares worth roughly $10.08 billion.
Then, Zanganeh Mahkam bought 5,000 shares, generating $90,350 in total proceeds. Upon buying the shares at $18.07, the Co-Chief Executive Officer now owns 556,093,090 shares.
Before that, DUGGAN ROBERT W bought 333,394 shares. Summit Therapeutics Inc shares valued at $5,894,406 were divested by the Co-Chief Executive Officer at a price of $17.68 per share. As a result of the transaction, DUGGAN ROBERT W now holds 556,088,090 shares, worth roughly $10.08 billion.
Guggenheim initiated its Summit Therapeutics Inc [SMMT] rating to a Buy in a research note published on September 04, 2025; the price target was $40. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in mid August with a ‘”a Neutral”‘ rating. UBS began covering SMMT with “Buy” recommendation on July 01, 2025. Leerink Partners started covering the stock on June 11, 2025. It rated SMMT as “an Underperform”.
Price Performance Review of SMMT
On Tuesday, Summit Therapeutics Inc [NASDAQ:SMMT] saw its stock fall -4.33% to $18.12. Over the last five days, the stock has lost -3.75%. Summit Therapeutics Inc shares have fallen nearly -33.89% since the year began. Nevertheless, the stocks have risen 1.54% over the past one year.
How much short interest is there in Summit Therapeutics Inc?
A steep rise in short interest was recorded in Summit Therapeutics Inc stocks on 2025-08-29, dropping by -1.28 million shares to a total of 29.72 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 30.99 million shares. There was a decline of -4.3%, which implies that there is a negative sentiment for the stock.
